AsiaNet Daily Summary - Press Releases for Wednesday, January 3, 2007

Press Releases »

SYDNEY--3 Jan--


ASTRAZENECA ANNOUNCES...

ALDERLEY PARK: AstraZeneca has announced submission of a supplemental New Drug Application to the US Food and Drug

Administration to seek approval for a new indication for SEROQUEL (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder.
http://www.astrazenecapressoffice.com
http://www.dbsalliance.org/PDF/IntroBrochureC2.pdf
http://www.dbsalliance.org/media/bipolarfacts.html

SEVEN WONDERS...

ZURICH: The Chairman of a panel of leading architectural experts has announced the 21 world's landmark sites which will

take part in the final stage of the race to become one of the New 7 Wonders of the World.
http://www.n7w.com/download
http://www.new7wonders.com

AsiaNet is a consortium of leading news agencies distributing unedited, translated news releases for worldwide clients. Visit www.asianetnews.net for full-text versions.


ข่าวbipolar disorder+AstraZenecaวันนี้

IEAT Partners with AstraZeneca, DLPW, and SSO to Launch a Social Initiative "Lung Screening with AI Innovation"

IEAT Partners with AstraZeneca, DLPW, and SSO to Launch a Social Initiative To Improve Quality of Life and Build a Sustainable Health Model for Thai Workers, featuring the "Lung Screening with AI Innovation" to Reduce COPD and Lung Cancer The Industrial Estate Authority of Thailand (IEAT), under the Ministry of Industry, has partnered with AstraZeneca (Thailand) Co., Ltd., the Department of Labor Protection and Welfare (DLPW), and the Social Security Office (SSO) under the Ministry of Labor, to

Strengthening Thailand's Clinical Researc... HSRI and AstraZeneca Sign an MOU to Advance Clinical Research in MoPH Hospitals Nationwide — Strengthening Thailand's Clinical Research Transformation, HS...

Over One Thousand Psychiatrists Gather Online for Second Asia Pacific Psychiatry Symposium

Discussion focusing on new therapeutic targets for schizophrenia and challenges in diagnosing and treating bipolar disorder The Second Asia Pacific Psychiatry Symposium hosted by Luye Pharma Group took place as...

ผลสำรวจเผยการสนับสนุนจากครอบครัวและการรักษาอย่างต่อเนื่องช่วยให้ผู้ป่วยทางจิตใช้ชีวิตตามปกติได้

จิตแพทย์ทั่วโลกร่วมกันเผนแพร่วิธีรักษาผู้ป่วยทางจิตอย่างยั่งยืน ผู้ป่วยทางจิตขั้นรุนแรง อาทิ โรคจิตเภท (schizophrenia), โรคก้ำกึ่งระหว่างจิตเภทกับอารมณ์แปรปรวน (schizoaffective) และโรคอารมณ์แปรปรวนสองขั้ว ...

Survey Highlights How Family Support and Finding and Staying on the Right Treatment Can Make a Difference in Keeping Patients with Serious Mental Illness Well

sychiatrists Worldwide Provide Insights into Essentials of Patient Care Patients with serious mental illness, such as schizophrenia,...

New Data Offers Hope to Patients With Bipolar Disorder and Schizophrenia

Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years...

Treating Both Poles of Bipolar Disorder: Pivotal Study Confirms Potential of Quetiapine as First Atypical Antipsychotic Monotherapy

For Healthcare and Medical Reporters (non-US and non-UK) The results of a pivotal study confirm the potential of quetiapine fumarate (SEROQUEL) as a monotherapy ...

ข้อมูลใหม่แนะนำว่า ยา ริสเพอตัล หรือ ยา ริสเพอริโดน เมื่อรับประทานตัวยานี้อย่างเดียวจะเป็นการรักษาอาการไบโพล่า มาเนีย

ติตัสวิลล์, เอ็น.เจ., 10 ธ.ค. พีอาร์นิวส์ไวร์/เอเชียเน็ท ผู้ที่มีอาการไบโพล่า ดิสออร์เดอร์ (bipolar disorder) หรือเป็นที่รู้จักกันในอาการคลุ้มคลั่งและซึมเศร้า หลังจากได้รับการรักษา...

New Data Suggests Risperdal(R) (Risperidone) Can Effectively Relieve Symptoms When Used Alone to Treat Bipolar Mania

TITUSVILLE, N.J., Dec. 11 PRNewswire/AsiaNet Individuals with bipolar disorder (also known as manic depression) experience significant relief of manic symptoms when treated with...